4:41 PM · 7 June 2021

Biogen trading paused after company received approval for its Alzheimer's drug

Biogen (BIIB.US) stock has been halted  after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.

Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5

8 September 2026, 2:44 PM

US Open: NFP Has Shifted Fed Expectations, and Wall Street Now Awaits Inflation

8 September 2026, 12:58 PM

ASML is picking up pace again.

8 September 2026, 11:37 AM

Novartis shares fall the most since 2020 📉 What is behind the 10% decline?

7 September 2026, 1:58 PM

Market Wrap: Far-right AfD wins in Germany, oil continues to rise (07.09.2026)

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits